Silence Therapeutics Plc - ADR
SLN
Get informed when a big investor buys or sells
+ FollowMarket Cap$648.05M
Close$
$0.10
99.3% downside
Current Fair Value
99.3% downsideOvervalued by 99.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $648.05 Million |
|---|---|
| Enterprise Value | $575.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.89 |
| Beta | 1.35 |
| Outstanding Shares | 47,236,587 |
Return
| Return on Equity | -101.36% |
|---|---|
| Return on Assets | -36.65% |
| Return on Invested Capital | -80.87% |
Valuation & Multiples
| P/E Ratio | -6.26 |
|---|---|
| PEG | 11.36 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 936.4 |
| Enterprise Value to EBIT | -7.6 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$1.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$1.12 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.6667▲ 166.67% |
|---|---|
| Total Calls | 18,900▲ Infinity% |
| Total Puts | 31,500▼ 20.85% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 42.15%▲ 3.85% |
|---|---|
| Total Invested | $102.08M▼ 3.77% |
| Investors Holding | 58▼ 1.00% |
ESG Score
No data
About Silence Therapeutics Plc
74 employees
CEO: David Solomon